CLINICAL RESEARCH: CARDIOMYOPATHY
Prevalence, Clinical Significance, and Genetic Basis of Hypertrophic Cardiomyopathy With Restrictive Phenotype
Toru Kubo, MD*, ,
Juan R. Gimeno, MD*,
Ajay Bahl, MD*,
Ulla Steffensen*,
Morten Steffensen*,
Eyman Osman, BSc*,
Rajesh Thaman, MD*,
Jens Mogensen, MD, PhD*, ,
Perry M. Elliott, MD, FACC*,
Yoshinori Doi, MD, FACC and
William J. McKenna, MD, FACC*,*
* Department of Medicine, University College London, London, United Kingdom
Department of Medicine and Geriatrics, Kochi Medical School, Kochi, Japan
Department of Cardiology, Skejby University Hospital, Aarhus, Denmark.
Manuscript received October 18, 2006;
revised manuscript received February 1, 2007,
accepted February 5, 2007.
* Reprint requests and correspondence: Dr. William J. McKenna, The Heart Hospital, University College London Hospitals Trust, 16-18 Westmoreland Street, London W1G 8PH, United Kingdom. (Email: william.mckenna{at}uclh.nhs.uk).
Objectives: The purpose of this study was to determine the prevalence, clinical significance, and genetic basis of hypertrophic cardiomyopathy (HCM) with "restrictive phenotype" characterized by restrictive filling and minimal or no left ventricular hypertrophy.
Background: Hypertrophic cardiomyopathy is a heterogeneous myocardial disorder with a broad spectrum of clinical presentation and morphologic features. Recent reports indicated that some patients with restrictive cardiomyopathy, which is an uncommon condition defined by restrictive filling and reduced diastolic volumes with normal or near normal left ventricular wall thickness and contractile function, have features suggestive of HCM with mutations in cardiac troponin I, myocyte disarray at explant/autopsy, and relatives with HCM. Systematic evaluation of the restrictive phenotype in HCM patients has not been performed.
Methods: We evaluated 1,226 patients from 688 consecutive HCM families to identify individuals who fulfilled diagnostic criteria for "restrictive phenotype."
Results: Nineteen of 1,226 affected individuals (1.5%) from 16 families (2.3%) had the "restrictive phenotype." During follow up (53.7 ± 49.2 months), 17 patients (89%) experienced dyspnea (New York Heart Association functional class  2). The 5-year survival rate from all-cause mortality, cardiac transplantation, or implantable cardioverter-defibrillator discharge was 56.4%. Mutation analysis for 5 sarcomere genes was feasible in 15 of 16 probands. Mutations were found in 8: 4 in beta-myosin heavy chain, and 4 in cardiac troponin I.
Conclusions: The "restrictive phenotype" in isolation is an uncommon presentation of the clinical spectrum of HCM and is associated with severe limitation and poor prognosis. This phenotype may be associated with beta-myosin heavy chain and cardiac troponin I mutations.
|
Abbreviations and Acronyms
| | CI = confidence interval | | E/A = peak E-wave/A-wave velocity ratio | | FS = fractional shortening | | HCM = hypertrophic cardiomyopathy | | ICD = implantable cardioverter-defibrillator | | LV = left ventricular | | LVEDD = left ventricular end-diastolic diameter | | LVESD = left ventricular end-systolic diameter | | LVH = left ventricular hypertrophy | | MLVWT = maximum left ventricular wall thickness | | MYBPC3
= cardiac myosin-binding protein C gene | | MYH7
= beta-myosin heavy chain gene | | RCM = restrictive cardiomyopathy | | R-E = Romhilt-Estes | | TNNI3
= cardiac troponin I gene | | TNNT2
= cardiac troponin T gene | | TPM1
= alpha-tropomyosin gene |
|
Related Article
-
Phenotypic Plasticity of Sarcomeric Protein Mutations
- Ali J. Marian
J. Am. Coll. Cardiol. 2007 49: 2427-2429.
[Full Text]
[PDF]
This article has been cited by other articles:
|
|
|
|
 
S. Carballo, P. Robinson, R. Otway, D. Fatkin, J. D.H. Jongbloed, N. de Jonge, E. Blair, J. P. van Tintelen, C. Redwood, and H. Watkins
Identification and Functional Characterization of Cardiac Troponin I As a Novel Disease Gene in Autosomal Dominant Dilated Cardiomyopathy
Circ. Res.,
August 14, 2009;
105(4):
375 - 382.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S Sivasankaran
Restrictive cardiomyopathy in India: the story of a vanishing mystery
Heart,
January 1, 2009;
95(1):
9 - 14.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
P Elliott and P Spirito
Prevention of hypertrophic cardiomyopathy-related deaths: theory and practice
Heart,
October 1, 2008;
94(10):
1269 - 1275.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. N. DeMaria, J. J. Bax, O. Ben-Yehuda, P. Clopton, G. K. Feld, G. S. Ginsburg, B. H. Greenberg, J. D. Knoke, W. Y.W. Lew, J. A.C. Lima, et al.
Highlights of the year in JACC 2007.
J. Am. Coll. Cardiol.,
January 29, 2008;
51(4):
490 - 512.
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. R. Pinto, M. S. Parvatiyar, M. A. Jones, J. Liang, and J. D. Potter
A Troponin T Mutation That Causes Infantile Restrictive Cardiomyopathy Increases Ca2+ Sensitivity of Force Development and Impairs the Inhibitory Properties of Troponin
J. Biol. Chem.,
January 25, 2008;
283(4):
2156 - 2166.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W.H. W. Tang and G. S. Francis
The Year in Heart Failure
J. Am. Coll. Cardiol.,
December 11, 2007;
50(24):
2344 - 2351.
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y. M. Hoedemaekers, K. Caliskan, D. Majoor-Krakauer, I. van de Laar, M. Michels, M. Witsenburg, F. J. ten Cate, M. L. Simoons, and D. Dooijes
Cardiac {beta}-myosin heavy chain defects in two families with non-compaction cardiomyopathy: linking non-compaction to hypertrophic, restrictive, and dilated cardiomyopathies
Eur. Heart J.,
November 2, 2007;
28(22):
2732 - 2737.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. J. Marian
Phenotypic Plasticity of Sarcomeric Protein Mutations
J. Am. Coll. Cardiol.,
June 26, 2007;
49(25):
2427 - 2429.
[Full Text]
[PDF]
|
|
|
|
